# Advantech Capital

> Advantech Capital is a VC fund backing Biotechnology and Pharmaceutical. See 41 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Central, Hong Kong
- Total investments: 41
- Last investment: Jun 2026
- Lead investor: 49%
- Fund size: $350M
- Last fund: Aug 2015
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/advantech
- Website: http://www.advantechcapital.com

Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China.

## Contacts

5 contacts available for Advantech Capital. Shizune tracks 5 team members at Advantech Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/advantech-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 14 | 34% |
| Pharmaceutical | 11 | 27% |
| Health Care | 10 | 24% |
| Medical | 7 | 17% |
| Therapeutics | 6 | 15% |

55 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 16 | 39% |
| Series A | 9 | 22% |
| Series C | 3 | 7% |
| Series D | 2 | 5% |
| Series E | 2 | 5% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 26 | 63% |
| United States | 6 | 15% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Hebert Kee Chan Pang | Director | 0 | https://shizune.co/investors/profile/hebert-kee-chan-pang |
| Jennifer Jin | Partner | 1 | https://shizune.co/investors/profile/jennifer-jin |
| Benjamin Qiu | Partner | 6 | https://shizune.co/investors/profile/benjamin-qiu |
| Jianming Yu | Founder, Managing Partner | 1 | https://shizune.co/investors/profile/jianming-yu |
| Jianming Yu | Founder, Managing Partner | 1 | https://shizune.co/investors/profile/jianming-yu-4564 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Spot Biosystems | Spot BioSystems is a bioengineering firm that specializes in personalized cancer treatments. The company's headquarters are in Palo Alto, California. | $40M | Venture - Series Unknown | Jun 17, 2026 |  |
| ELITE Technology | Elite's seven-axis collaborative robot uses the latest deep neural network (DNN) technology to identify irregularly shaped objects and accurately capture them. Through the fusion of 2D and 3D data, the accuracy requirements of the depth vision sensor are reduced, the success rate of the capture is improved, the versatility of the grabbingsystem is enhanced, and the hybrid object capture is supported. The system can be widely used in 3C, logistics, retail, catering and other industries. |  | Series C | Mar 11, 2022 |  |
| CureGenetics | Cure Genetics is a biotechnology company developing cutting-edge applications of technologies in innovative medicines and molecular diagnostics for the next-generation treatment of cancers and genetic diseases. | $60M | Series B | Jan 05, 2022 |  |
| Mojo Vision | Mojo Vision is a developer of augmented reality products and platforms intended to invent the future of computing. The company has developed a smart contact lens with a built-in display that gives timely information without interrupting the focus and delivers immediate, powerful, and relevant information without the intrusions of today'smobile devices, enabling users to connect with others at a glance, anytime, anywhere handsfree.Mojo Vision was founded in 2015 and headquartered in Saratoga, California. | $45M | Series B | Jan 04, 2022 |  |
| Innoforce Pharmaceuticals | Innoforce is a biopharma manufacturing firm that facilitates the development and commercialization of innovative medicines. | $58.8M | Series A | Dec 06, 2021 |  |
| Ablaze Pharmaceuticals | Ablaze Pharma is a clinical stage bio-pharmaceutical company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients. | $75M | Series A | Nov 29, 2021 |  |
| Zhimeng Biopharma | Zhimeng is also actively developing novel small molecule drugs to treat neurological diseases, such as epilepsy, pains and strokes. | $54.7M | Series B | Nov 08, 2021 |  |
| Boan Biotech | Boan Biotech is a biopharmaceutical company developing therapeutic antibodies with a focus on key therapeutic areas including oncology, metabolism, autoimmunity, and ophthalmology. | $18.8M | Series B | Oct 01, 2021 |  |
| Onconano Medicine | OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue.OncoNano Medicineis a UTSW spinoff company based in Dallas, Texas. | $50M | Series B | Jun 17, 2021 |  |
| Zhuanzhuan | Zhuanzhuan is an online marketplace on which users can buy and sell secondhand goods. Moreover, Zhuanzhuan operates as a goods trading unit of China's largest online marketplace, 58.com Launched in November 2015, the company is headquartered in China. | $100M | Series D | Jun 17, 2021 |  |

10 of 41 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 5 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 5 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 4 deals together
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 4 deals together
- [Tencent](https://shizune.co/investors/profile/tencent) — VC Fund, 4 deals together
- [CMB International Capital Corporation](https://shizune.co/investors/profile/cmbi-international-capital-corporation) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Advantech Capital invest in?

Advantech Capital invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Series A stage. Most of the 41 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Advantech Capital?

Public channels for Advantech Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Advantech Capital?

The team at Advantech Capital includes Hebert Kee Chan Pang (Director), Jennifer Jin (Partner) and Benjamin Qiu (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co